Vishay Precision Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vishay Precision Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $307.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $306.52M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $355.05M | Feb 27, 2026 |
| FY2018 | Dec 31, 2018 | $76.98M | Mar 14, 2019 |
| FY2018 | Sep 29, 2018 | $75.49M | Mar 14, 2019 |
| FY2018 | Jun 30, 2018 | $74.23M | Mar 14, 2019 |
| FY2018 | Mar 31, 2018 | $73.09M | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $69.44M | Mar 14, 2019 |
| FY2018 | Sep 30, 2017 | $62.81M | Mar 14, 2019 |
| FY2018 | Jul 1, 2017 | $62.32M | Mar 14, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $307.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $306.52M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $355.05M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $362.58M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $317.92M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $269.81M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $69.14M | Mar 11, 2020 |
| FY2019 | Sep 28, 2019 | $67.42M | Mar 11, 2020 |
| FY2019 | Jun 29, 2019 | $70.87M | Mar 11, 2020 |
| FY2019 | Mar 30, 2019 | $76.53M | Mar 11, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $125.53M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $150.34M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $149.60M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $125.14M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $104.27M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $24.17M | Mar 11, 2020 |
| FY2019 | Sep 28, 2019 | $25.79M | Mar 11, 2020 |
| FY2019 | Jun 29, 2019 | $28.61M | Mar 11, 2020 |
| FY2019 | Mar 30, 2019 | $33.05M | Mar 11, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.29M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $9.91M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $25.71M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $36.06M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $20.22M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $10.79M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $3.87M | Mar 11, 2020 |
| FY2019 | Sep 28, 2019 | $4.51M | Mar 11, 2020 |
| FY2019 | Jun 29, 2019 | $5.57M | Mar 11, 2020 |
| FY2019 | Mar 30, 2019 | $8.24M | Mar 11, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.85M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $16.86M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $41.95M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $43.80M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $27.37M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $22.66M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $1.76M | Mar 11, 2020 |
| FY2019 | Sep 28, 2019 | $6.19M | Mar 11, 2020 |
| FY2019 | Jun 29, 2019 | $8.10M | Mar 11, 2020 |
| FY2019 | Mar 30, 2019 | $12.60M | Mar 11, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.83M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $19.96M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $20.38M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $19.77M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $17.20M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $12.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $12.10M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $11.80M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $11.70M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $11.10M | Mar 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.64M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $107.51M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $106.83M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $104.29M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $95.27M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $78.26M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $79.62M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $80.94M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $73.75M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $68.38M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.38M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $19.82M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $45.89M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $33.03M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $33.54M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $35.31M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $30.93M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $35.38M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $22.73M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $11.51M | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $455.89M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $450.94M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $471.57M | Feb 25, 2025 |
| FY2024 | Dec 31, 2022 | $476.74M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $461.89M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $401.89M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $370.41M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $326.38M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $306.55M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $270.51M | Mar 14, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.66M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $129.08M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $141.64M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $170.22M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $184.85M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $144.03M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $128.66M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $107.93M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $113.25M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $98.95M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $336.37M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $321.97M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $329.84M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $306.55M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $277.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $257.82M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $241.36M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $218.42M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $193.16M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $171.38M | Mar 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.37M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $46.82M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $45.73M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $45.54M | Feb 27, 2026 |
| FY2023 | Dec 31, 2021 | $45.83M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $31.11M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $35.02M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $16.14M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $19.18M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $18.72M | Mar 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.27M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $191.98M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $182.07M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $156.36M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $120.30M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $100.08M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $89.29M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $66.57M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $43.08M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $28.73M | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.37M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $79.27M | Feb 27, 2026 |
| FY2023 | Dec 31, 2023 | $83.97M | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $88.56M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $84.34M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $98.44M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $86.91M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $90.16M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $74.29M | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $58.45M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.58M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $31.44M | Feb 27, 2026 |
| FY2021 | Dec 31, 2021 | $60.71M | Mar 4, 2022 |
| FY2021 | Dec 31, 2020 | $40.64M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $44.53M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $27.08M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $32.36M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $36.15M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $33.16M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $22.83M | Mar 9, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 11, 2020 |
| FY2019 | Sep 28, 2019 | 0 | Mar 11, 2020 |
| FY2019 | Jun 29, 2019 | 0 | Mar 11, 2020 |
| FY2019 | Mar 30, 2019 | 0 | Mar 11, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 11, 2020 |
| FY2019 | Sep 28, 2019 | 0 | Mar 11, 2020 |
| FY2019 | Jun 29, 2019 | 0 | Mar 11, 2020 |
| FY2019 | Mar 30, 2019 | 0 | Mar 11, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 12.41M | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | 12.55M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 12.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 12.55M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | 12.50M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 12.45M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 12.27M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 12.17M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | 12.14M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | 12.73M | Mar 9, 2016 |